You are a pharmacist investigating the molecular details of a new synthetic drug designed as a cancer therapeutic. The drug is a small peptide designed to block a growth factor from binding to its receptor. Thus preventing the transcription of a cell cycle protein. Describe in detail how an experiment would show whether it was likely to work at the molecular level Note the drug is a peptide and it binds to the growth factor which interacts with a receptor. Protein:protein interaction

answers

watching

234

views

For unlimited access to Homework Help, a Homework+ subscription is required.

You have 0 free answers left.
Get unlimited access to 3.8 million step-by-step answers.

Get unlimited access

Already have an account? Log in

iloveyou2023Lv10

23 Nov 2023

Unlock all answers

Get 1 free homework help answer.

Already have an account? Log in

You have 0 free answers left.
Get unlimited access to 3.8 million step-by-step answers.

Get unlimited access

Already have an account? Log in

teacherrecoLv10

23 Jul 2023

Already have an account? Log in

You have 0 free answers left.
Get unlimited access to 3.8 million step-by-step answers.

Get unlimited access

Already have an account? Log in

yoru5Lv10

16 May 2022

Already have an account? Log in

You have 0 free answers left.
Get unlimited access to 3.8 million step-by-step answers.

Get unlimited access

Already have an account? Log in

Deanna HettingerLv2

9 Jan 2018

Already have an account? Log in

Related questions

1.In 1971, Dr. Judah Folkman published the âangiogenic hypothesisâ suggesting that a tumor cannot grow beyond 1â2 millimeters without the development of new blood vessels (angiogenesis) that provide access to oxygen and nutrients. During the 1990s, it was discovered that vascular endothelial growth factor (VEGF) stimulates migration and proliferation of the cells that form blood vessels, leading to the formation of new blood vessels. VEGF binds to receptor tyrosine kinases (RTKs) on the cell surface and causes the RTKs to dimerize and become active, thereby initiating an intracellular signaling cascade that stimulates cell division and inhibits apoptosis. Many cancer cells secrete high levels of VEGF and increased VEGF expression in a tumor is correlated with a poor medical outcome for the patient. You work for a biotechnology company that seeks to create anti-cancer drugs that prevent growth of tumors and/or cause tumors to shrink, while leaving normal cells relatively untouched. Your company has purchased the rights to therapeutic uses of VEGF derived proteins as anti-tumor drugs. You have found that the VEGF protein has 2 domains, one involved in receptor binding, the other is required for dimerization of VEGF. You propose to make mutant versions of the protein that will act as antagonists of the receptor to be given to patients as an IV treatment as a way to inhibit the endogenous VEGF secreted by the tumor.

a.Which of the 2 domains should you mutate (receptor binding or dimerization)?

b. How do you expect the introduction of the mutant protein into the bloodstream of patients to block tumor progression (in other words, why did you change the domain in part a)?